Advantage Alpha Capital Partners LP Alkermes Plc. Transaction History
Advantage Alpha Capital Partners LP
- $361 Million
- Q1 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Alkermes Plc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 21,357 shares of ALKS stock, worth $558,058. This represents 0.2% of its overall portfolio holdings.
Number of Shares
21,357
Previous 13,947
53.13%
Holding current value
$558,058
Previous $401,000
75.81%
% of portfolio
0.2%
Previous 0.1%
Shares
6 transactions
Others Institutions Holding ALKS
# of Institutions
405Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$761 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$476 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$308 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$210 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$180 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.29B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...